These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23198862)

  • 41. Designer T-cells and T-cell receptors for customized cancer immunotherapies.
    Legut M; Sewell AK
    Curr Opin Pharmacol; 2018 Aug; 41():96-103. PubMed ID: 29852403
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene-engineered T cells for cancer therapy.
    Kershaw MH; Westwood JA; Darcy PK
    Nat Rev Cancer; 2013 Aug; 13(8):525-41. PubMed ID: 23880905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engineering T cells for adoptive therapy: outsmarting the tumor.
    Kunert A; Debets R
    Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.
    Eisenberg V; Hoogi S; Shamul A; Barliya T; Cohen CJ
    Adv Drug Deliv Rev; 2019 Feb; 141():23-40. PubMed ID: 30653988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.
    Coulie PG; Van den Eynde BJ; van der Bruggen P; Boon T
    Nat Rev Cancer; 2014 Feb; 14(2):135-46. PubMed ID: 24457417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. T cell-based gene therapy of cancer.
    Gill S; Kalos M
    Transl Res; 2013 Apr; 161(4):365-79. PubMed ID: 23246626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects.
    Kalos M
    Vaccine; 2003 Jan; 21(7-8):781-6. PubMed ID: 12531359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adoptive cell transfer as personalized immunotherapy for human cancer.
    Rosenberg SA; Restifo NP
    Science; 2015 Apr; 348(6230):62-8. PubMed ID: 25838374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.
    Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D
    Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric antigen receptor-modified T cells strike back.
    Frigault MJ; Maus MV
    Int Immunol; 2016 Jul; 28(7):355-63. PubMed ID: 27021308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Cancer with Genetically Engineered TCR T Cells.
    Smith TW; Nishimura MI
    Recent Results Cancer Res; 2020; 214():129-151. PubMed ID: 31473851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overcoming key challenges in cancer immunotherapy with engineered T cells.
    Arcangeli S; Mestermann K; Weber J; Bonini C; Casucci M; Hudecek M
    Curr Opin Oncol; 2020 Sep; 32(5):398-407. PubMed ID: 32796230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting.
    Sutherland AR; Owens MN; Geyer CR
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unleash the power of the mighty T cells-basis of adoptive cellular therapy.
    Sukari A; Abdallah N; Nagasaka M
    Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
    Curran KJ; Pegram HJ; Brentjens RJ
    J Gene Med; 2012 Jun; 14(6):405-15. PubMed ID: 22262649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Driving gene-engineered T cell immunotherapy of cancer.
    Johnson LA; June CH
    Cell Res; 2017 Jan; 27(1):38-58. PubMed ID: 28025979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.